Effect ofDexmedetomidine on General Anesthesia in Patients Undergoing Staging Surgery for Ovarian Cancer
Objective:To Objective to analyze the effect of dexmedetomidine in general anesthesia for patients under-going staged ovarian cancer surgery.Methods:From June 2022 to December 2023,90 patients with ovarian cancer undergoing staged surgery were selected and randomly divided into observation group(given dexmedetomidine)and control group(given normal saline).The levels of inflammatory factors、T lymphocyte subsets and adverse reac-tions were compared between the two groups at different anesthesia time.Results:At T0,the levels of IL-1β、IL-6、TNF-α and high-sensitivity C-reactive protein in the two groups were compared,P＞0.05;At T1 and T2,the levels of inflammatory factors in both groups decreased,and those in the observation group were lower than those in the control group,P＜0.05.T0,the comparison of CD3+、CD4+、CD8+and CD4+/CD8+between the two groups,P＞0.05;At T1 and T2,T lymphocyte subsets in both groups increased,and the observation group was higher than the control group,P＜0.05.The incidence of adverse reactions between the two groups was compared,P＞0.05.Conclusion:Dexmedetomidine is effective and safe in general anesthesia for patients undergoing staged ovarian cancer surgery,which can reduce inflammatory reaction,effectively improve T lymphocyte subsets and improve pa-tients'immune function.
General anesthesiaOvarian cancerInflammatory factorsDexmedetomidineImmune functionAd-verse reactions
国家科技期刊平台
NSTL
万方数据
